News
AVCTF
0.770
NaN%
--
Weekly Report: what happened at AVCTF last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at AVCTF last week (1026-1030)?
Weekly Report · 11/02 09:38
Weekly Report: what happened at AVCTF last week (1019-1023)?
Weekly Report · 10/26 09:38
Weekly Report: what happened at AVCTF last week (1012-1016)?
Weekly Report · 10/19 09:38
Weekly Report: what happened at AVCTF last week (1005-1009)?
Weekly Report · 10/12 09:40
Weekly Report: what happened at AVCTF last week (0928-1002)?
Weekly Report · 10/05 09:40
Weekly Report: what happened at AVCTF last week (0921-0925)?
Weekly Report · 09/28 09:38
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
Barchart · 09/25 01:00
Weekly Report: what happened at AVCTF last week (0914-0918)?
Weekly Report · 09/21 09:38
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
Barchart · 09/16 10:00
Weekly Report: what happened at AVCTF last week (0907-0911)?
Weekly Report · 09/14 09:40
Weekly Report: what happened at AVCTF last week (0831-0904)?
Weekly Report · 09/07 09:37
Weekly Report: what happened at AVCTF last week (0824-0828)?
Weekly Report · 08/31 09:40
Weekly Report: what happened at AVCTF last week (0817-0821)?
Weekly Report · 08/24 09:41
Weekly Report: what happened at AVCTF last week (0810-0814)?
Weekly Report · 08/17 09:41
Weekly Report: what happened at AVCTF last week (0803-0807)?
Weekly Report · 08/10 09:39
Weekly Report: what happened at AVCTF last week (0727-0731)?
Weekly Report · 08/03 09:39
Weekly Report: what happened at AVCTF last week (0720-0724)?
Weekly Report · 07/27 09:41
Weekly Report: what happened at AVCTF last week (0713-0717)?
Weekly Report · 07/20 09:39
Weekly Report: what happened at AVCTF last week (0706-0710)?
Weekly Report · 07/13 09:40
More
Webull provides a variety of real-time AVCTF stock news. You can receive the latest news about Avacta Group through multiple platforms. This information may help you make smarter investment decisions.
About AVCTF
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.